, Tracking Stock Market Picks
Enter Symbol:
Exelixis, Inc. (EXEL) [hlAlert]

up 45.69 %

Exelixis, Inc. (EXEL) rated Buy by Merriman Curhan Ford

Posted on: Thursday,  Oct 16, 2008  8:25 AM ET by Merriman Curhan Ford

Merriman Curhan Ford rated Buy Exelixis, Inc. (NASDAQ: EXEL) on 10/16/2008, when the stock price was $4.18. Since
then, Exelixis, Inc. has gained 45.69% as of 08/27/2015's recent price of $6.09.
If you would have followed this Merriman Curhan Ford's recommendation on EXEL, you would have gained 45.69% of your investment in 2506 days.

Exelixis, Inc. (Exelixis) is developing therapies for cancer and other serious diseases. Through its drug discovery and development activities, the Company is building a portfolio of novel compounds. Exelixis has a pipeline of compounds in various stages of development that will potentially treat cancer, renal disease and various metabolic and cardiovascular disorders. Its most advanced pharmaceutical programs focus on drug discovery and development of small molecule drugs for cancer. The Company has nine compounds in clinical development: XL184, XL147, XL765, XL518, XL228, XL019, XL139, XL413 and XL888. Exelixis also has out-licensed to third parties for further development and commercialization of five compounds in preclinical and clinical development: XL880, XL281, XL652, XL550 and FXR Program. The Company has established commercial collaborations with several pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, Genentech, Inc. and GlaxoSmithKline.

We occupy a unique niche among our investment banking peers: we offer our clients both traditional sell-side equity research and primary market research, and we focus on high-potential sectors such as CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. Our institutional and corporate clients get the best of both worlds: expertise from our analysts and access to experts through our Panel Intelligence platform.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/16/2008 8:25 AM Buy
as of 12/24/2008
1 Week down  -8.68 %
1 Month up  6.46 %
3 Months down  -1.59 %
1 YTD down  -1.59 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy